07/03/2025 09:22

ResMed Inc (RMD) $35.65

Sleep disorder business RMD fell 3.4% on Thursday, making it the standout loser in the healthcare sector after founder Peter Farrell sold $500k worth of shares.

Read more

13/02/2025 09:28

ResMed Inc (RMD) $37.55

Sleep disorder business RMD has slipped from all-time highs after reporting its quarterly results last week. The weakening trend in organic sales overshadowed the strong financial performance. This remains an impressive business, but after recovering strongly from Ozempic worries in 2024, we must consider what is next.

Read more

03/02/2025 17:14

ResMed (RMD) $38.94

RMD -3.09%: Reported quarterly results in the US on Friday that were solid on first pass, though the market has latched onto a weaking trend from organic sales which overshadowed the strong financial performance.

Read more

09/08/2024 09:27

ResMed Inc (RMD) $32.52

Sleep apnoea company RMD has experienced a wild ride over the last year as news from weight loss companies has impacted its share price week to week more than specific news about the company itself. Earlier this month, RMD delivered a largely in-line 4Q, with revenue and core EPS both close to consensus. Revenue growth was 9% y/y and core EPS showed 30% growth y/y.

Read more

30/07/2024 09:27

ResMed Inc (RMD) v Dexcom (DXCM US)

RMD fell over 2% on Monday following an update from Nasdaq-listed Dexcom (DXCM US). The US-listed stock plunged over 40%, its largest drop in history, after they reported disappointing revenue and lowered its full-year guidance. Dexcom offers a suite of tools, such as continuous glucose monitors, for patients who have been diagnosed with diabetes.

Read more

26/04/2024 09:17

ResMed Inc (RMD US) $US183.42

ResMed reported after the US market closed this morning with Q3 adjusted EPS of $2.13 ahead of the consensus of $1.91, a result that’s likely to be welcomed locally this morning, with the stock up ~5% in late trade. Earnings were helped by revenue of $1.2bn, which was 7.2% ahead of consensus; its quarterly dividend was maintained at 48c. Today's price action will be interesting as MM is not keen on stocks that cannot rally on “good news.”

Read more

17/04/2024 09:35

ResMed (RMD) versus CSL Ltd (CSL)

The Australian Healthcare is trading at a ~70% premium to the ASX 200 on a 1-year forward PE, which is close to its recent normal; hence, we are considering switching with the sector as opposed to outright buying or selling. RMD & CSL are two very different healthcare businesses, although both suffered in 2023 at the hands of Ozempic et al.. In both cases, the sell-off was over-blown in our opinion, but that’s the nature of stocks when the crowd runs as one.

Read more

12/04/2024 09:03

ResMed Inc (RMD) $29.56

RMD rallied +1.5% in a falling market on Thursday, an encouraging move for the sleep disorder business, which has been on a wild Ozempic ride over the last year – unfortunately, overnight trade in the US suggests it will struggle this morning. At MM, we’ve commented on many of RMD’s twists and turns through its volatile journey since many of us first heard about miracle slimming drugs, and after its 43% recovery, the risk/reward is diminishing fast for the bulls.

Read more

28/03/2024 09:41

ResMed Inc (RMD) $29.93

RMD’s been on a wild Ozempic ride in 2023/4, but its recent ~40% bounce has restored a semblance of calm/normality to the stock. However, we shouldn't forget that RMD took an initial sharp downturn last August after an FY23 earnings miss; this weakness was compounded by demand concerns as the benefits of weight loss drugs got increasing media coverage. At some stage, we can see RMD entering a “holding pattern” as investors wait to see the difference between fact and fiction.

Read more

14/03/2024 08:47

ResMed Inc. (RMD) $29.08

Ozempic et al. have made the last year a particularly torrid and uncertain time for sleep apnoea company RMD. In simple terms, if these new wonder drugs lead to fewer people carrying weight, it will theoretically reduce the demand for RMD products. After bouncing over 40% from its panic 2023 low, we are contemplating trimming our 5% holding from purely a volatility perspective.

Read more